SHINE - Stroke Hyperglycemia Insulin Network Effort
Registered with ClinicalTrials.gov: NCT01369069
NIH Project Number: 5U01NS069498-05
Status: Enrollment Closed
Congratulations SHINE team on the completion of SHINE enrollment with 1151 subjects!
Please join us as Dr. Karen C. Johnston presents the primary results of the SHINE trial on behalf of the entire SHINE team on February 6, 2019 at 11:23 AM (HST) during the ISC Plenary Session in Honolulu, Hawaii.
This is a multicenter, prospective, randomized, controlled trial, with blinded outcomes. It aims to determine the efficacy and provide further safety data on the use of insulin infusion therapy for glucose control in hyperglycemic acute ischemic stroke patients. Treatment with insulin infusion will be given within 12 hours of symptom onset. The primary outcome to be assessed at 90 days will be the difference in favorable outcome measured by the modified Rankin Scale score in the insulin infusion group compared to the control group. The rates of symptomatic hypoglycemia with prolonged neurological worsening as well as asymptomatic hypoglycemia will be assessed. The secondary outcomes will assess additional neurological and functional outcomes. This highly collaborative research program is nearly guaranteed to advance the field of stroke care.